Mystery San Diego party inks $300m deal with Abzena for antibody linking tech

By Dani Bancroft

- Last updated on GMT

Mystery San Diego party inks $300m deal with Abzena for ADC tech

Related tags License

An unnamed San Diego-based firm has signed a licensing agreement for Abzena Plc’s ThioBridge antibody drug conjugate (ADC) linker technology.

ThioBridge is a platform which links antibodies and other proteins to drugs, to help maintain stability of the antibody and a consistent Drug-to-Antibody Ratio​ (DAR), which reduces risk of unwanted side effects.

The unidentified firm will be the fifth private party to license Abzena’s linker technologies, with the deal allowing for use of ThioBridge​ on up to 10 ADCs across a range of indications.

“Abzena and the US biopharmaceutical company has enjoyed an ongoing collaborative research programme to evaluate ThioBridge up until now,” ​said John Burt, CEO of Abzena.

“The collaboration has allowed both parties to build a strong working relationship and to demonstrate the value of the ThioBridge technology in creating novel ADCs.”

This new deal could potentially earn Abzena over $300 million, including milestone payments, with further earnings on sales royalties of any approved products using the technology.

The firm’s share prices jumped over 62% in response to the news.

Feature Image: iStock/Goir

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us